Should I buy, hold, or sell LFCR stock right now?

Lifecore Biomedical Inc. (LFCR) currently earns a Roarable Rating of C- (Hold — HOLD) with 59/100 RQD Confidence. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.

What is LFCR's 12-month price target and RQD AI Jury consensus?

LFCR's 12-month base price target is $6.43 (range $5.02 to $9.43), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Stock Ratings / Health Care / LFCR

IMRX (30) EVMN (31) IFRX (54) CAMP (26) ⌘ Pro Terminal →

Lifecore Biomedical Inc. (LFCR) — RQD Stock Rating Cockpit

$6.40 -1.84% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.37

Lifecore Biomedical Inc. (LFCR) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $242.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LFCR Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LFCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Lifecore Biomedical Inc. (NASDAQ: LFCR) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $6.40 (-1.84% 1D, market cap $242.3M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, LFCR ranks #173 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LFCR compare to IMRX and EVMN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LFCR carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, IMRX (Immuneering Corporation (Class A)) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $242.5M) and EVMN (Evommune Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $244.2M). Among the 5-stock peer group, LFCR leads on earnings multiple (N/A) while IMRX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LFCR?

▼

Per LFCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001005286), Lifecore Biomedical Inc. generated $97.5M in revenue (-24.3% YoY), $0 in net income, and $0 in free cash flow against $232.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.37 (-0.52%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+0.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LFCR)Realized 20D OHLCV Swing Band: ±1.9%

Deterministic 5-Pillar Attribution (59/100 Composite)

🔍 WHY LFCR SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (24% of score)

20D Institutional Volume Accumulation (±1.9% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$6.42-0.8% Next Q

Q2 (-2Q)

Grade C+$6.37+1.1% Next Q

Q3 (-1Q)

Grade C+$6.44-0.6% Next Q

Current

Grade C-$6.40+0.2% Hist 90D α

Trajectory: B- (67) → C- (59)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the LFCR Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 59/100 (C-) score, LFCR faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($5.50) or 200D SMA ($5.49) invalidates the momentum regime and cuts Target Base ($6.43) toward Bear Floor ($5.02).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LFCR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LFCR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 59%NO 41%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

61.730 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE52% OF RANGE

L: $4$6.40H: $9

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: D+RQD 11 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: D+RQD 23 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 25 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on LFCR

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (55)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (58)

23/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like LFCR

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (LFCR Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LFCR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +24.76%📐 HORIZONTAL RANGE

2026-11-03O $6.52H $6.52L $6.40C $6.40VOL 1.02M

RES: $7.34SUP: $3.89SMA50: $5.50SMA200: $5.49

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LFCR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LFCR Butterfly Map → + Track LFCR →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -24.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LFCR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LFCR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LFCR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LFCR)

Health Care Rank #173 of 1015 ⚔️ IMRX vs LFCR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LFCR vs. IMRX, EVMN, IFRX, CAMP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Lifecore Biomedical Inc. (LFCR) ranks #173 by composite RQD confidence (59/100, grade C-) and #548 by equity capitalization ($242.3M). Within this direct 5-issuer industry benchmark cohort, LFCR leads on earnings valuation at N/A trailing P/E, while IMRX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LFCR currently leads its immediate peer cohort in composite quantitative strength at 59/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LFCR ACTIVE Lifecore Biomedical Inc.	C-	59/100	—	—	—	-1.84%	$242.3M	Benchmark Subject
IMRX Immuneering Corporation (Class A)	E	30/100	—	—	-35.0%	-6.84%	$242.5M	/imrx-vs-lfcr →
EVMN Evommune Inc.	E	31/100	—	—	-35.0%	-1.17%	$244.2M	/evmn-vs-lfcr →
IFRX InflaRx N.V.	D+	54/100	—	—	—	-3.21%	$244.6M	/ifrx-vs-lfcr →
CAMP CAMP4 Therapeutics Corporation	E	26/100	—	—	-35.0%	+1.54%	$248.5M	/camp-vs-lfcr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001005286 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lifecore Biomedical Inc. (LFCR) reported GAAP revenue of $97.5M (-24.3% vs. FY2024 revenue of $128.9M , and +293.8% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, LFCR closed FY2025 with $232.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$97.5M	$0	—	—	$232.2M	—
FY2024 (FY)	2024-05-25	$128.9M	-$38.7M	-$206.0K	-$13.6M	$255.4M	$110.5M
FY2023 (FY)	2023-05-26	$24.8M	$12.0M	$257.0K	$257.0K	—	—

3. LFCR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LFCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does LFCR compare to IMRX and EVMN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for LFCR?

Where is LFCR trading relative to its 50-day, 200-day, and 52-week technical levels?

LFCR last traded at $6.40 (-1.84% on volume of 1,023,945 shares), positioning the stock +16.36% above its 50-day simple moving average ($5.50) and +16.58% above its 200-day simple moving average ($5.49). Across its 52-week range of $3.63 to $8.98, LFCR sits at the 51.8% percentile with a 14-day RSI of 61.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±1.9% ($6.28 to $6.52).

Direct Sub-Reports: LFCR RQD Cockpit LFCR 12M Forecast LFCR Earnings & Move LFCR Dividends & DRIP LFCR Insiders & 13F LFCR Whale Options LFCR Profit Sankey LFCR News & Why

ROARABLE RATING BRIEF • RQD 59/100 (C-) ✓ SEC XBRL & RQD VERIFIED

LFCR — Lifecore Biomedical Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Lifecore Biomedical Inc. (LFCR) earns a live Roarable RQD composite score of 59/100, corresponding to a C- letter grade (Roarable Hold) at a spot price of $6.40 (-1.84% 1D, market capitalization $242.3M).

Fundamental Cash Engine (11/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (14/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (12/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. (LFCR) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. — for product lines, customers, or revenue model specifics beyond the sector and industry classification.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Lifecore Biomedical Inc. (LFCR) reported $97.5M in annual revenue (up from $128.9M in FY2024, -24.3% YoY) and $0 in GAAP net income. Over the multi-year SEC filing window from FY2023 ($24.8M revenue, $12.0M net income) through FY2025, LFCR scaled operating cash flow to $0 and free cash flow to $0, backed by $232.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (C- • RQD 59/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 14/20. With Fundamental Cash Engine at 11/20 and Institutional Whale Flow at 14/20, sustained execution supports upside toward the upper end of the $3.63 – $8.98 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies are — Sector correlation data is — Second-order bottlenecks cannot be identified from the supplied sources.

Key Question #1: Can LFCR sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $97.5M and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is LFCR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

LFCR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Lifecore Biomedical Inc. (LFCR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LFCR Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 23h ago

Lifecore Biomedical to Participate at Upcoming Industry Conferences

Yahoo Finance report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

Lifecore Biomedical Q2 2026 Earnings Call Transcript

Benzinga report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Supply Chain Digital • 1d ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR), WaFd, Inc. (Nasdaq – WAFD)

Supply Chain Digital report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Lifecore Biomedical (LFCR) Short Interest & Short Float | Updated Oct 2026 $LFCR

MarketBeat report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE WBOC TV • 1d ago

Are RXO, PTC, LFCR, WAFD Obtaining Fair Deals for their Shareholders?

WBOC TV report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Lifecore Biomedical, Inc. (LFCR) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 1d ago

The Technical Signals Behind (LFCR) That Institutions Follow

Stock Traders Daily report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 8d ago

Braemar Unveils Highly Qualified Independent Board Slate for Company’s New Chapter

DALLAS, October 26, 2026--Braemar Hotels & Resorts Inc. (NYSE: BHR) ("Braemar" or the "Company") today announced that its Board of Directors (the "Board") intends to nominate eight highly qualified, seasoned leaders for

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LFCR Bull vs. Bear Conversation Board — What's Your Call at $6.40?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LFCR 🐻 33% BEARISH CONVICTION

DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $8.26 (+29.1%)

📌 Pinned Debate

The Forensic Balance Sheet pillar (13/20, Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) and the Whale 13F Flow pillar (13/20) indicat

The street is overcomplicating Lifecore Biomedical Inc. (LFCR). The Forensic Balance Sheet pillar (13/20, Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) and the Whale 13F Flow pillar (13/20) indicate financial survival metrics and some institutional interest are relatively stronger than the earnings base.. With an RQD score of 59/100 (C-) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $6.91.

SectorRotator 🐂 BULL

@SkepticalCFA Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $5.18 (-19.1%)

Spot @ $6.40

The Fundamental Cash Engine pillar scores 11/20 with ROIC at 0% and FCF yield at 0%, and FY 2024 shows a net loss of -$38.7M on $128.9M

Careful chasing LFCR at $6.40. The Fundamental Cash Engine pillar scores 11/20 with ROIC at 0% and FCF yield at 0%, and FY 2024 shows a net loss of -$38.7M on $128.9M revenue.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $5.18 on multiple compression.